What I'd buy before the ASX rebounds: 3 high-conviction share picks

Analysts think these shares are strong buys before the market rebound.

| More on:
A man holding a cup of coffee puts his thumb up and smiles while at laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It is fair to say that the ASX has taken a major hit this month. But here's the thing: markets don't fall forever — and when the rebound comes, it tends to reward those who stayed calm and acted early.

Rather than trying to call the bottom, I'm focused on identifying businesses that I believe will come out stronger on the other side. These are companies with world-class leadership, strong balance sheets, and the kind of resilience that lets them keep delivering no matter what the market throws at them.

In addition, brokers have named them as buys recently and are tipping big returns over the next 12 months. Here are three ASX shares I'd be buying before the rebound:

CSL Ltd (ASX: CSL)

There's a reason CSL has been a favourite among long-term investors for decades: it is one of the few true global biotech leaders on the ASX. But after an extended period of underperformance, sentiment has turned — and CSL is trading well below its historical valuation multiples.

Nevertheless, the company's fundamentals remain incredibly strong. Its core plasma business has recovered and is on course for strong growth in the coming years and its R&D pipeline is packed with high-potential therapies.

With healthcare demand growing globally and biotech innovation accelerating, CSL is a long-term earnings machine trading at a rare discount. That's the kind of mismatch I like to take advantage of.

Goldman Sachs currently rates CSL as a buy with a $307.30 price target.

Goodman Group (ASX: GMG)

In a market dominated by short-term noise, Goodman plays the long game — and plays it well. This is no ordinary property stock. Goodman owns and develops high-end logistics, warehousing, and data centre infrastructure for some of the world's biggest and most forward-thinking companies.

Think Amazon. Think next-generation industrial hubs.

What makes Goodman different is its combination of capital discipline, development smarts, and exposure to powerful themes like e-commerce, AI, and data infrastructure.

As the ASX stabilises and ASX growth shares come back into focus, I suspect Goodman could be one to lead the charge.

This week, Morgans upgraded its shares to an add rating with a $35.30 price target.

Pro Medicus Ltd (ASX: PME)

Finally, Pro Medicus has never been the cheapest share on the ASX — and with good reason. Its health imaging software is used by leading hospitals around the world, and its contracts stretch out years into the future, locking in high-margin recurring revenue.

But with its shares getting caught up in the tech selloff, I see a compelling opportunity for investors. Especially given how the company continues to win major contracts and its platform is becoming increasingly entrenched in the global healthcare system.

Pro Medicus isn't just growing — it is compounding. And for investors who understand the power of long-term recurring revenue, this kind of business is hard to beat.

Goldman Sachs is also a big fan of this ASX share. The broker has a buy rating and $307.00 price target on it shares.

Motley Fool contributor James Mickleboro has positions in CSL, Goodman Group, and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Goldman Sachs Group, and Goodman Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Goodman Group, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Two plants grow in jars filled with coins.
Growth Shares

3 ASX 200 growth stocks up more than 100% in 1 year that could charge higher

It's been a memorable year for shareholders of these 3 companies.

Read more »

Afterpay share price a happy shopper with a wide mouthed smile holds multiple shopping bags up around her shoulders.
Growth Shares

The pros and cons of buying Zip shares in June

Should investors buy now or wait until later?

Read more »

A smiling woman holds a Facebook like sign above her head.
Growth Shares

3 ASX growth shares I'd buy for the next 10 years

Let's see why these shares could be top picks for the long term.

Read more »

wheelchair user in an office talking on mobile phone
Growth Shares

Why I'd buy this ASX growth share instantly

I’m calling on this stock to deliver strong returns.

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Growth Shares

2 ASX growth shares to buy in June: experts

These businesses have strong growth potential.

Read more »

Rocket powering up and symbolising a rising share price.
Growth Shares

Buy these stellar ASX growth shares with $1,000

Analysts think these shares would be top buys right now.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Growth Shares

These ASX growth shares could rise 18% to 30%

Let's see which shares are being tipped to rocket.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Growth Shares

Goldman Sachs tips this ASX 200 growth stock to rise 35%

Let's see what the broker is saying about this growing company.

Read more »